Market Exclusive

Analyst Upgrades – Endocyte (NASDAQ:ECYT) Stock Gets Upgraded By Wedbush from Neutral to Outperform

Analyst Ratings For Endocyte (NASDAQ:ECYT)

Today, Endocyte (NASDAQ:ECYT) stock received an upgrade by Wedbush from Neutral to Outperform.

There are 1 hold rating, 2 buy ratings on the stock.

The current consensus rating on Endocyte (NASDAQ:ECYT) is Buy (Score: 2.67) with a consensus target price of $4.50 per share, a potential 23.97% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Endocyte (NASDAQ:ECYT)
Endocyte (NASDAQ:ECYT) has insider ownership of 14.86% and institutional ownership of 28.80%.

Recent Trading Activity for Endocyte (NASDAQ:ECYT)
Shares of Endocyte closed the previous trading session at with shares trading hands.

Exit mobile version